MiNA Therapeutics Presents New Pre-Clinical Data from Sickle Cell Disease Program at the European Hematology Association 2025 Congress

Contributed by: Business Wire

Logo

Tags

Science

Biotechnology

Research

Pharmaceutical

General Health

Health

Health Technology

Genetics

MTL-HBG

More Like This

MiNA Therapeutics Presents New Data for its HbF Program at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

PR Newswire associated0

Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer

e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025

PR Newswire associated0

BIAL Announces Oral Presentation at GBA1 Meeting 2025

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, a Novel Investigational RNAi MASH Candidate